SC
NKTR icon

SRB Corp’s Nektar Therapeutics NKTR Stock Holding History

SRB Corp’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-991
Closed -$529K – 173
2019
Q2 		$529K Sell
991
-207
-17% -$104K 0.05% 31
2019
Q1 		$604K Buy
1,198
+163
+16% +$96.6K 0.06% 118
2018
Q4 		$511K Buy
1,035
+482
+87% +$291K 0.05% 77
2018
Q3 		$505K Buy
+553
New +$472K 0.05% 136

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRB Corp's NKTR Position: Q3 2019 in Review

SRB Corp sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 991 shares — an estimated $529K sold.

SRB Corp first reported a position in NKTR in Q3 2018 and held it in 4 quarters. The position peaked at $604K in Q1 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • SRB Corp reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • SRB Corp sold 991 Nektar Therapeutics shares in Q3 2019, an estimated $529K.
  • SRB Corp first reported a position in Nektar Therapeutics in Q3 2018 and held it in 4 quarters.
  • SRB Corp's Nektar Therapeutics position peaked at $604K in Q1 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on SRB Corp's 13F filing for Q3 2019, filed 14 Nov 2019.